Paper37720348
Nuclear epidermal growth factor receptor as a therapeutic target.
Atwell B and 2 others. Explor Target Antitumor Ther, 2023. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Nuclear epidermal growth factor receptor as a therapeutic target. Papers, record 37720348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37720348
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References87
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35295841 | Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/35295841 | PubMed |
| 2 | 21266349 | EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. | Cancer Res | 2011 | https://conductscience.org/library/papers/21266349 | PubMed |
| 3 | 21520037 | A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. | Int J Cancer | 2011 | https://conductscience.org/library/papers/21520037 | PubMed |
| 4 | 18723476 | Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18723476 | PubMed |
| 5 | 32053675 | Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. | PLoS One | 2020 | https://conductscience.org/library/papers/32053675 | PubMed |
| 6 | 8638121 | Enhanced degradation of EGF receptors by a sorting nexin, SNX1. | Science | 1996 | https://conductscience.org/library/papers/8638121 | PubMed |
| 7 | 21487020 | Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21487020 | PubMed |
| 8 | 22520625 | Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. | Cell Biosci | 2012 | https://conductscience.org/library/papers/22520625 | PubMed |
| 9 | 31747009 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/31747009 | PubMed |
| 10 | 32793488 | Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. | Front Oncol | 2020 | https://conductscience.org/library/papers/32793488 | PubMed |
| 11 | 1980216 | Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. | Biochemistry | 1990 | https://conductscience.org/library/papers/1980216 | PubMed |
| 12 | 31401198 | Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy. | J Control Release | 2019 | https://conductscience.org/library/papers/31401198 | PubMed |
| 13 | 29445288 | Prognostic significance of epidermal growth factor receptor expression in glioma patients. | Onco Targets Ther | 2018 | https://conductscience.org/library/papers/29445288 | PubMed |
| 14 | 25189483 | Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25189483 | PubMed |
| 15 | 19887552 | MUC1 oncoprotein is a druggable target in human prostate cancer cells. | Mol Cancer Ther | 2009 | https://conductscience.org/library/papers/19887552 | PubMed |
| 16 | 22665533 | TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22665533 | PubMed |
| 17 | 15665312 | Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/15665312 | PubMed |
| 18 | 33758141 | Nuclear EGFR Expression Is Associated With Poor Survival in Laryngeal Carcinoma. | Appl Immunohistochem Mol Morphol | 2021 | https://conductscience.org/library/papers/33758141 | PubMed |
| 19 | 19058255 | Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. | Mol Carcinog | 2009 | https://conductscience.org/library/papers/19058255 | PubMed |
| 20 | 35427766 | EGFR signaling pathway as therapeutic target in human cancers. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/35427766 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42040768 | From EGFR PTM network to TKI resistance: spatial subtypes and targeting in lung cancer. | Cancer Drug Resist | 2026 | https://conductscience.org/library/papers/42040768 | PubMed |
| 41871146 | The differential roles of Giardia duodenalis-secreted tenascins in inducing intestinal epithelial cell apoptosis and the attributed EGFR-STAT3 axis regulation. | PLoS Negl Trop Dis | 2026 | https://conductscience.org/library/papers/41871146 | PubMed |
| 41420294 | Tissue Proteomics of Feline Mammary Carcinoma: Differences in Protein Profiles Among Histological Grades Using Liquid Chromatography-Tandem Mass Spectrometry. | Vet Comp Oncol | 2026 | https://conductscience.org/library/papers/41420294 | PubMed |
| 41228309 | SH003 as a Redox-Immune Modulating Phytomedicine: A Ferroptosis Induction, Exosomal Crosstalk, and Translational Oncology Perspective. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228309 | PubMed |
| 40943631 | Real-Time Kinetics of Internalization of Anti-EGFR DNA Aptamers and Aptamer Constructs into Cells Derived from Glioblastoma Patients as Indicated by Doxorubicin. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943631 | PubMed |
| 39940647 | Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray (Potamotrygon spp.) as a Drug Carrier in Glioblastoma Cancer Cells. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39940647 | PubMed |
| 39456666 | Epidermal Growth Factor Intralesional Delivery in Chronic Wounds: The Pioneer and Standalone Technique for Reversing Wound Chronicity and Promoting Sustainable Healing. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39456666 | PubMed |
Genes38
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37720348
GET https://conductscience.org/api/papers/v1/37720348/references?page=2